title: Use of systemic therapy in women with recurrent ovarian cancer--development of a national clinical practice guideline.
abstract: OBJECTIVE
  To develop a guidance document concerning the use of systemic therapy for women with recurrent ovarian cancer that would be applicable for the Canadian health care system. This will be done using a standardized systematic review process, guideline evaluation instruments, multi-disciplinary expert consensus opinion and evidence-rating systems.
  
  
  METHODS
  The primary data sources were MEDLINE, National Guideline Clearinghouse and Cochrane Library.
  
  
  METHODS
  Clinical practice guidelines, technology assessments, systematic reviews and randomized controlled trials addressing systemic therapy for women with recurrent ovarian cancer were eligible.
  
  
  METHODS
  Data was identified and extracted by the methodology team and reviewed by the authors. Results were reviewed and discussed by members of an expert working group comprised of a multidisciplinary and geographic divergent group of practitioners.
  
  
  RESULTS
  The existing 7 practice guidelines underwent formal evaluation for quality, currency and content using the AGREE tool. Recommendations with evidence-ratings were developed. This data was used by a pan-Canadian panel in an informal consensus process, which resulted in the initial draft of a guideline. The guideline team reviewed the draft and made further edits to ensure the guideline's appropriateness for a national context. Practitioner feedback was requested from 165 health care providers who treat ovarian cancer from across Canada. Overall response rate was 37% and was very positive. Comments were reviewed and the guideline was edited appropriately.
  
  
  CONCLUSIONS
  The development of a national practice guideline on the use of systemic therapy for recurrent ovarian cancer was feasible using systematic literature review, expert consensus, guideline evaluation instruments, evidence-rating systems, independent internal and external review measures and final approval by a national discipline specific society (GOC). Recommendations for practice are offered.
authors.affiliation: Juravinski Cancer Centre, Hamilton, Ontario, Canada. laurie.elit@hrcc.on.ca <laurie.elit@hrcc.on.ca>
authors.forename: L
authors.initials: L
authors.lastname: Elit
authors.forename: L
authors.initials: L
authors.lastname: Zitzelsberger
authors.forename: M
authors.initials: M
authors.lastname: Fung-Kee-Fung
authors.forename: M
authors.initials: M
authors.lastname: Brouwers
authors.forename: I D
authors.initials: ID
authors.lastname: Graham
authors.forename: G
authors.initials: G
authors.lastname: Browman
authors.forename: P
authors.initials: P
authors.lastname: Hoskins
authors.forename: S
authors.initials: S
authors.lastname: Lau
authors.forename: P
authors.initials: P
authors.lastname: Ghatage
mesh_terms: D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D010051:Ovarian Neoplasms / Q000628:therapy*; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic